N = 373 | Subjects | Incident AF cases | Incidence rate (per 1000 person-years) | Model 1 h (95%CI) | Model 2 h (95%CI) |
---|---|---|---|---|---|
NT-proBNP and SVEs | |||||
 Non-elevated NT-proBNP, infrequent SVEs | 220 | 35 | 9.49 | Ref | Ref |
 Elevated NT-proBNP, infrequent SVEs | 59 | 12 | 15.07 | 1.45 (0.75, 2.80)†| 1.52 (0.76, 3.05)†|
 Non-elevated NT-proBNP, frequent SVEs | 60 | 22 | 25.30 | 2.48 (1.45, 4.26) | 2.32 (1.33, 4.06)†|
 Elevated NT-proBNP, frequent SVEs | 34 | 19 | 47.05 | 4.19 (2.30, 7.65) | 4.61 (2.45, 8.69) |
Interaction NT-proBNP * SVEs |  |  |  | P = 0.740 | P = 0.582 |
NT-proBNP and SVTs | |||||
 Non-elevated NT-proBNP, infrequent SVTs | 214 | 31 | 8.68 | Ref | Ref |
 Elevated NT-proBNP, infrequent SVTs | 61 | 16 | 20.24 | 1.99 (1.08, 3.67) | 2.03 (1.07, 3.87)‡ |
 Non-elevated NT-proBNP, frequent SVTs | 66 | 26 | 26.08 | 2.52 (1.48, 4.29) | 2.26 (1.30, 3.95) |
 Elevated NT-proBNP, frequent SVTs | 32 | 15 | 36.66 | 3.55 (1.88, 6.70) | 4.46 (2.24, 8.88) |
Interaction NT-proBNP *SVTs |  |  |  | P = 0.443 | P = 0.945 |
NT-proBNP and SVA | |||||
 Non-elevated NT-proBNP, non-elevated SVA | 195 | 28 | 8.54 | Ref | Ref |
 Elevated NT-proBNP, non-elevated SVA | 53 | 12 | 17.11 | 1.74 (0.88, 3.44)§ | 1.76 (0.86, 3.62)§ |
 Non-elevated NT-proBNP, elevated SVA | 85 | 29 | 22.63 | 2.23 (1.32, 3.79) | 2.10 (1.21, 3.65)§ |
 Elevated NT-proBNP, elevated SVA | 40 | 19 | 38.10 | 3.65 (1.98, 6.73) | 4.33 (2.26, 8.31) |
Interaction NT-proBNP *SVA |  |  |  | P = 0.894 | P = 0.740 |